Article 23
2022
Diagnosis of adrenocortical carcinoma with hypercortisolism in a patient presenting with hypokalemic metabolic alkalosis
Omair Khan Maimonides Medical Center Sheharyar Raashid Isolation hospital and infection treatment
Muhammad Hashim Shifa International Hospital, muhammadhashim412@outlook.com
Kevin Clements Maimonides Medical Center
Sanjay Maheshwari Maimonides Medical Center
See next page for additional authors
Follow this and additional works at: https://scholarlycommons.gbmc.org/jchimp
Recommended Citation
Khan, Omair; Raashid, Sheharyar; Hashim, Muhammad; Clements, Kevin; Maheshwari, Sanjay; Uddin, Syed Mohammad Mazhar; Siriya, Pranay; Vadsariya, Aftab; Park, Patricia; and Pascal, William (2022) “Diagnosis of adrenocortical carcinoma with hypercortisolism in a patient presenting with hypokalemic metabolic alkalosis,” Journal of Community Hospital Internal Medicine Perspectives: Vol. 12: Iss. 5, Article 23. DOI: 10.55729/2000-9666.1108 Available at: https://scholarlycommons.gbmc.org/jchimp/vol12/iss5/23
This Case Report is brought to you for free and open access by the Journal at GBMC Healthcare Scholarly Commons. It has been accepted for inclusion in Journal of Community Hospital Internal Medicine Perspectives by an authorized editor of GBMC Healthcare Scholarly Commons. For more information, please contact GBMCcommons@gbmc.org.
Diagnosis of adrenocortical carcinoma with hypercortisolism in a patient presenting with hypokalemic metabolic alkalosis
Authors
Omair Khan, Sheharyar Raashid, Muhammad Hashim, Kevin Clements, Sanjay Maheshwari, Syed Mohammad Mazhar Uddin, Pranay Siriya, Aftab Vadsariya, Patricia Park, and William Pascal
Diagnosis of Adrenocortical Carcinoma with Hypercortisolism in a Patient Presenting with Hypokalemic Metabolic Alkalosis
Omair Khan ª,*, Sheharyar Raashid b, Muhammad Hashim , Kevin Clements ª, Sanjay Maheshwari ª, Syed M. Mazhar Uddin ª, Pranay Siriya a, Aftab Vadsariya a, Patricia Park d, William Pascal e
a Resident Physician, Maimonides Medical Center, United States
b Isolation Hospital and Infection Treatment Center Islamabad, Pakistan
· Intern, Shifa International Hospital, Pakistan
d Endocrinology, Maimonides Medical Center, United States
e Pulmonary and Critical Care, Maimonides Medical Center, United States
Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated annual incidence of 0.7-2 cases per million. Most patients present with steroid hormone excess or abdominal mass effects, but 15% of patients with ACC are diagnosed incidentally. A careful history, physical exam, and pertinent lab investigations are necessary to reach the diagnosis. Surgical resection is the cornerstone of treatment in localized ACC; however, systemic chemotherapy with mitotane is preferred in patients with widespread disease or those who are not ideal candidates for surgery.
Keywords: Adrenal cancer, Hypercortisolism, Adrenal mass, Cushingoid adrenal cancer
Introduction
P hysicians often encounter patients with elec- trolyte derangements and are tasked with un- derstanding why they occur. The ability to form many diagnoses that can play a role in such de- rangements is necessary to treat patients appropri- ately. We present the case of a patient with severe hypokalemia secondary to adrenocortical carcinoma (ACC). ACC is a very high-grade malignancy with a poor prognosis (1). Patient’s can present with signs of hormone overproduction. However, most of the time ACC is diagnosed incidentally. Managing ACC can be a challenge. Localized tumors can be surgi- cally resected, whereas chemotherapy is offered to patients with metastatic ACC.
1. Case presentation
57-year-old male with past medical history of schizoaffective disorder and recently diagnosed hypertension who was brought to the emergency department after he had a fall and hit his head. On admission, the patient’s vital signs were normal with a blood pressure of 140/100. Physical exam was unremarkable. The patient had no family history of cancer. His baseline labs showed hypokalemia with a potassium level of 1.8 (3.6-5.2 mmol/L) and metabolic alkalosis with bicarbonate of 41 (22-29 mEq/L). The patient’s home medications included furosemide and antipsychotics. After admission, patient suddenly became hypoxic and was requiring oxygen via nasal cannula. CT scan and MRI abdomen/pelvis showed a large right adrenal mass
Received 7 May 2022; revised 27 June 2022; accepted 8 July 2022. Available online 9 September 2022
* Corresponding author at:
E-mail address: omair.khn@outlook.com (O. Khan), sheharyar_93@hotmail.com (S. Raashid), muhammadhashim412@outlook.com (M. Hashim), Kclements@maimonidesmed.org (K. Clements), Smaheshwari@maimonidesmed.org (S. Maheshwari), syed_mazhar92@hotmail.com (S.M. Mazhar Uddin), siriya.pranay@gmail.com (P. Siriya), aftabvadsariya@gmail.com (A. Vadsariya), Papark@maimonidesmed.org (P. Park), Wpascal@ maimonidesmed.org (W. Pascal).
https://doi.org/10.55729/2000-9666.1108
2000-9666/ 2022 Greater Baltimore Medical Center. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
F
measuring 15.5 × 9.8 cm in axial dimension and 16.2 cm in cranio-caudal dimension respectively (Figs. 1 and 2).
Workup for adrenal mass showed aldosterone 7.7 (<23.2 ng/dl), direct renin 9.1 (<33.2 pg/ml) with a ratio of 0.85, ruling out primary hyperaldosteronism. His cortisol was 47.8 (6.7-27.60 Ug/dl) and the repeat was 48 after dexamethasone suppression test was performed. His ACTH was <1.5 (7.2-63 pg/ml), pointing towards primary hypercortisolism. Other significant labs findings included DHEA sulfate of
520 (70-310 ug/dl), 17-hydroxyprogesterone of 310 (27-199 ng/dl) and androstenedione of 103 (40-150 ng/dl). His HbA1C (<6.5%) also jumped up from 6 to 9 in the last 6 months. Due to the risk of malignancy, interventional radiology was consulted to biopsy the adrenal mass. Pheochromocytoma was ruled out before the biopsy as the plasma meta- nephrines 28.9 (0-244 pg/dl) and normetanephrine 16.2 (0-88 pg/dl) were within normal limits. Mean- while, the patient was started on lisinopril and spi- ronolactone, and potassium was repleted as needed. He was started on insulin regimen for the new onset diabetes. Biopsy confirmed the diagnosis of adrenal cortical carcinoma, myxoid variant (Fig. 3). Immu- nohistochemical staining (Inhibin+, Melan-A+, Calretinin, Synaptophysin+) supported an adrenal cortical phenotype (Fig. 4).
Urology was consulted for surgery but due to the locally advanced adrenocortical carcinoma with liver invasion and extension into the inferior vena cava, the decision was made not to proceed due to the high risk of morbidity and mortality. The patient was planned for chemotherapy with mitotane and was transferred to an adrenal facility for better care. Patient was eventually lost to follow up.
2. Discussion
Adrenocortical carcinoma (ACC) is a very rare and aggressive endocrine tumor, with a reported incidence
A
B
C
D
of 0.5-2 cases per million, occurring more commonly in women.1 Majority of the cases have already metas- tasized at the time of diagnosis, most commonly involving the lymph nodes, lungs, liver and bone. Due to its aggressive nature, detection at initial stages is associated with better surgical outcomes. About 60% of the patients present with symptoms of hormone excess, which may manifest in the form of Cushing syndrome, electrolyte abnormalities or virilization, whereas non-specific symptoms like abdominal full- ness and flank pain may be seen in the rest of the pa- tients having non-functioning tumors. Hypercortisolism is the most common manifestation of a functional ACC, which was seen in our patient. Most patients will have suppressed ACTH and increased cortisol when checked at 08:00 am. Hyper- cortisolism is confirmed by a 1 mg dexamethasone suppression test, midnight salivary cortisol or elevated 24-h free cortisol in urine.2 Other supportive lab findings include elevated serum glucose and adrenal androgens. High urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) are also indicative of ACC. There are various distinct histological mor- phologies of this tumor, and among these the myxoid variant is a very rare and aggressive subtype, which was seen in our patient. The differential diagnoses in adults include Cushing syndrome, renal cell carci- noma, hyperaldosteronism and hyperandrogenism, whereas those in children include nephroblastoma, neuroblastoma, and metastatic adrenal deposits. Our patient had an elevated cortisol level with a biopsy proven adrenocortical carcinoma. Normal plasma aldosterone to renin ratio (ARR) and normal androgen levels ruled out primary hyperaldosteronism and hyperandrogenism, respectively. Approximately 30% of the ACCs are diagnosed incidentally while scanning for other medical issues.4 Diagnostic modalities include biochemical and hormonal tests, imaging (such as CT, MRI, and FDG-PET scan), and confir- mation of diagnosis via histopathology after biopsy.5 Complete surgical excision is the premier treatment option. Other treatment options entail a multi-disci- plinary approach and include mitotane systemic therapy, cytotoxic chemotherapy, radiation therapy, radiofrequency ablation, and immunotherapy. Mito- tane, by virtue of its adrenolytic activity, reduces local recurrence and can be used in advanced ACC when surgery isn’t a viable option, and thus was used in the treatment of our patient.º The prognosis for ACC is poor, with 5-year survival rates hovering around 15-44%.7 Older age, functioning tumor, advanced stage at diagnosis, and incomplete resection are the main clinical factors associated with poor survival. Recurrence is frequently seen following a complete resection. Median time of recurrence is 1 year.
Surveillance includes CT of the chest and abdomen every 3 months along with monitoring of steroid hor- mones.8 Ultrasound has shown clinical significance during follow up of selected patients.9
3. Conclusion
We encountered a rare case of Cushingoid adre- nocortical carcinoma. It is very crucial to diagnose it early, as its poor prognosis and overall survival can largely be attributed to its aggressive nature and diagnosis at advanced stages. Complete surgical resection remains the mainstay of treatment offering the best chance for long term survival; however, adjuvant chemotherapy and radiotherapy can be offered to high-risk patients. Regular follow up plans should be established due to the high recur- rence rate of such tumors.
Financial disclosure
The authors received no financial support for the research, authorship, and publication of this article.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgment
The authors like to thank Dr Jeffrey Lipton MD at Maimonides Medical Center for providing the bi- opsy images.
References
1. Sharma E, Dahal S, Sharma P, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10(8):636-640. https://doi.org/ 10.14740/jocmr3503w.
2. Chiodini I, Ramos-Rivera A, Marcus AO, Yau H. Adrenal hypercortisolism: a closer look at screening, diagnosis, and important considerations of different testing modalities. J Endocr Soc. 2019;3(5):1097-1109 Published 2019 Apr 11. https://doi.org/10.1210/js.2018-0038.
3. Shetty I, Fuller S, Raygada M, et al. Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma [published online ahead of print, 2020 Jan 8]. Endo- crinol Diabetes Metab Case Rep. 2020;2020:19-147. https:// doi.org/10.1530/EDM-19-014.
4. Dietrich CF, Correas JM, Dong Y, Nolsoe C, Westerway SC, Jenssen C. WFUMB position paper on the management inci- dental findings: adrenal incidentaloma. Ultrasonography. 2020; 39(1):11-21. https://doi.org/10.14366/usg.1902.
5. Almuallem S, Abualhamael S, Mosli H, Mosli H, Aljiffry M. Adrenocortical carcinoma in a young patient: report of a rare case and review of the literature at king Abdulaziz University hospital. Int Arch Urol Complic. 2018;4(48). https://doi.org/ 10.23937/2469-5742/1510048.
6. Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma -
review and state of the art. Eur Endocrinol. 2018;14(2):62-66. https://doi.org/10.17925/EE.2018.14.2.6.
7. Kuthiah N, Er C. A case of metastatic adrenocortical carci- noma. Oxf Med Case Reports. 2019;2019(2):omz006 Published 2019 Feb 27. https://doi.org/10.1093/omcr/omz00.
8. Chatzoulis G, Passos I, Bakaloudi DR, et al. Giant nonfunc- tioning adrenal tumors: two case reports and review of the
literature. J Med Case Rep. 2018;12:335. https://doi.org/10.1186/ s13256-018-1876-8.
9. Kou K, Zhang H, Zhang C, et al. A case of adrenocortical carcinoma accompanying secondary acute adrenal hypo- function postoperation. World J Surg Oncol. 2018;16:43. https:// doi.org/10.1186/s12957-018-1326-5.